Could cause temporary or reversible harm; serious harm is unlikely.
Crystallization; identified as Buprenorphine free base
| Brand name | BUPRENORPHINE HYDROCHLORIDE |
| Generic name | BUPRENORPHINE HYDROCHLORIDE |
| Active ingredient(s) | BUPRENORPHINE HYDROCHLORIDE |
| Distributed by / for | Endo USA, Malvern, PA 19855 |
| NDC | 42023-179-05 |
| Full product label | Buprenorphine Hydrochloride, Injection, 0.3mg/mL, 5x1 mL Single Dose Vials, Rx only, Manufactured for: Endo USA, Malvern, PA 19855, NDC 42023-179-05. |
| Recalling firm | ENDO USA, Inc. |
| Distribution | USA Nationwide |
| Quantity | 34,293 vials |
| Recall initiated | 2026-03-13 |
| Report date | 2026-05-20 |
| Recall completed | — |
| Recall number | D-0527-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Rochester MI United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗